Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) Rating Reiterated at Piper Jaffray Cos.

Analysts at Piper Jaffray Cos. reiterated a Hold rating on shares of Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) in a reserach note to investors, making it one of the more actively watched stocks on Wall Street. Piper Jaffray Cos. currently has a rating of Hold on the stock. As a means of comparison, a number of other analysts have commented on the stock in recent days, and the company has secured a consensus one-year price target of $467.45, above the opening price of $406.47. Regeneron Pharmaceuticals Inc. stock has a 52-week high of $592.59. Usually, after analysts issue a “reiterated rating” report on a stock, they will subsequently issue other revisions, such as a price target change.

U.S. stocks closed higher Tuesday as investors anticipate the results of meetings from the Federal Reserve and the Bank of Japan.

The Dow Jones Industrial Average DJIA, +0.05% rose 9.79 points, or less than 0.1%, to close at 18,129.96.

The S&P 500 index SPX, +0.03% advanced 0.64 points to finish at 2,139.76, led by gains in the health-care and consumer-staples sectors.

The Nasdaq Composite index COMP, +0.12% gained 6.33 points, or 0.1%, to close at 5,241.35.

Shares of Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) opened at $406.47 yesterday trading between $400.23 and $407.29, and last traded at $406.24, which is an increase of $3.41 over the previous closing price.

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) currently has a market cap of 42.51B.

626,928 shares traded hands yesterday, 120 percent below normal, out of a total float 71,486,000. Investors often use swings in trading volume to determine substantial volume growth or distribution by institutional investors, so look for trading volume to pick up in the coming days.

As with all possible breakouts, investors watch for volume to be at least 40%-50% greater than normal on the breakout to demonstrate that fund managers and other professional investors are jumping in.

Institutional sponsorship is defined by ownership of a stock by mutual funds, banks, pension funds and other large institutions.

Institutional investors such as these have substantial teams of analysts that investigate thousands of stocks, so it is good validation to see them buying a stock you’re considering.

Traders are able to make make more useful choices on trades when they track the activity of professional investors.

Trades for Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) have ranged from $329.09 – 592.59, and the stock now has a 50-day MA of $408.70 and 200-day MA of $389.50. Today’s last price is 0.31% lower than the 52 week high of $592.59.

Indeed, earnings growth is among the most crucial things to look at in regards to stock investing and, accordingly, investors seek companies that have increased their earnings at least 25% or more over the past 3 years.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.